Sigyn Therapeutics, Inc. Announces Executive Changes
October 24, 2020 at 12:31 am IST
Share
Sigyn Therapeutics, Inc. announced In connection with the Agreement, on October 19, the current officers and directors of the Company resigned, and concurrently, the Company appointed new officers and a new board of directors as follows, James Joyce Chairman and CEO and Director, Craig Roberts CTO and Director.
Sigyn Therapeutics, Inc. (Sigyn) is a development-stage company. The Company is focused on creating therapeutic solutions that address unmet needs in global health. The Company's product candidate, Sigyn Therapy, is a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders. Its treatment indications include endotoxemia and inflammation in end-stage renal disease (dialysis) patients, sepsis (a cause of hospital deaths), community-acquired pneumonia (a cause of death among infectious diseases), and emerging pandemic threats. Sigyn Therapy is a single-use disposable device that is deployable on the global infrastructure of hemodialysis and continuous renal replacement therapy (CRRT) machines. The Companyâs development pipeline includes a cancer treatment system comprised of ChemoPrep to enhance the tumor site delivery of chemotherapy, and ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis.